A detailed history of Geode Capital Management, LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 4,331,314 shares of ESPR stock, worth $9.66 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,331,314
Previous 4,159,705 4.13%
Holding current value
$9.66 Million
Previous $9.23 Million 22.61%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.61 - $2.73 $276,290 - $468,492
171,609 Added 4.13%
4,331,314 $7.15 Million
Q2 2024

Aug 09, 2024

BUY
$1.84 - $3.24 $4.43 Million - $7.8 Million
2,406,512 Added 137.26%
4,159,705 $9.23 Million
Q1 2024

May 13, 2024

BUY
$2.02 - $3.02 $1.29 Million - $1.94 Million
640,947 Added 57.63%
1,753,193 $4.7 Million
Q4 2023

Feb 13, 2024

BUY
$0.73 - $3.08 $103,665 - $437,384
142,008 Added 14.64%
1,112,246 $3.33 Million
Q3 2023

Nov 13, 2023

BUY
$0.96 - $1.79 $140,861 - $262,648
146,731 Added 17.82%
970,238 $950,000
Q2 2023

Aug 11, 2023

SELL
$1.2 - $1.76 $596,772 - $875,265
-497,310 Reduced 37.65%
823,507 $1.14 Million
Q1 2023

May 15, 2023

BUY
$1.46 - $7.3 $59,703 - $298,518
40,893 Added 3.19%
1,320,817 $2.1 Million
Q4 2022

Feb 13, 2023

BUY
$5.09 - $8.5 $775,430 - $1.29 Million
152,344 Added 13.51%
1,279,924 $7.97 Million
Q3 2022

Nov 14, 2022

BUY
$5.45 - $8.13 $175,315 - $261,525
32,168 Added 2.94%
1,127,580 $7.55 Million
Q2 2022

Aug 12, 2022

SELL
$4.77 - $6.67 $74,578 - $104,285
-15,635 Reduced 1.41%
1,095,412 $6.97 Million
Q1 2022

May 13, 2022

BUY
$3.34 - $5.56 $944,722 - $1.57 Million
282,851 Added 34.15%
1,111,047 $5.16 Million
Q4 2021

Feb 11, 2022

BUY
$4.81 - $11.92 $2.34 Million - $5.8 Million
486,325 Added 142.25%
828,196 $4.14 Million
Q3 2021

Nov 12, 2021

SELL
$11.34 - $21.37 $1.24 Million - $2.33 Million
-109,094 Reduced 24.19%
341,871 $4.12 Million
Q2 2021

Aug 13, 2021

BUY
$19.4 - $28.71 $44,658 - $66,090
2,302 Added 0.51%
450,965 $9.54 Million
Q1 2021

May 12, 2021

BUY
$25.12 - $36.89 $1.02 Million - $1.5 Million
40,791 Added 10.0%
448,663 $12.6 Million
Q4 2020

Feb 12, 2021

BUY
$24.2 - $35.76 $239,846 - $354,417
9,911 Added 2.49%
407,872 $10.6 Million
Q3 2020

Nov 13, 2020

BUY
$31.18 - $52.71 $297,581 - $503,064
9,544 Added 2.46%
397,961 $14.8 Million
Q2 2020

Aug 13, 2020

BUY
$30.04 - $51.31 $510,710 - $872,321
17,001 Added 4.58%
388,417 $19.9 Million
Q1 2020

May 14, 2020

BUY
$27.44 - $73.84 $695,329 - $1.87 Million
25,340 Added 7.32%
371,416 $11.7 Million
Q4 2019

Feb 13, 2020

SELL
$35.4 - $59.82 $251,304 - $424,662
-7,099 Reduced 2.01%
346,076 $20.6 Million
Q3 2019

Nov 12, 2019

BUY
$34.47 - $47.53 $142,326 - $196,251
4,129 Added 1.18%
353,175 $12.9 Million
Q2 2019

Aug 14, 2019

BUY
$40.1 - $52.33 $2.18 Million - $2.84 Million
54,332 Added 18.44%
349,046 $16.2 Million
Q1 2019

May 14, 2019

BUY
$40.11 - $53.57 $774,283 - $1.03 Million
19,304 Added 7.01%
294,714 $11.8 Million
Q4 2018

Feb 13, 2019

BUY
$36.99 - $59.11 $754,706 - $1.21 Million
20,403 Added 8.0%
275,410 $12.7 Million
Q3 2018

Nov 13, 2018

BUY
$40.74 - $51.41 $1.65 Million - $2.08 Million
40,382 Added 18.82%
255,007 $11.3 Million
Q2 2018

Aug 14, 2018

BUY
$36.2 - $76.4 $1.3 Million - $2.74 Million
35,882 Added 20.07%
214,625 $8.41 Million
Q1 2018

May 15, 2018

BUY
$65.94 - $80.76 $307,478 - $376,583
4,663 Added 2.68%
178,743 $12.9 Million
Q4 2017

Feb 13, 2018

SELL
$43.47 - $67.43 $110,022 - $170,665
-2,531 Reduced 1.43%
174,080 $11.5 Million
Q3 2017

Nov 14, 2017

BUY
$43.8 - $52.77 $1.52 Million - $1.83 Million
34,736 Added 24.48%
176,611 $8.85 Million
Q2 2017

Aug 14, 2017

BUY
N/A
141,875
141,875 $6.57 Million

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $148M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.